Background Recent studies have provided a detailed census of genes that are mutated in
acute myeloid leukemia (AML). Our next challenge is to understand how this genetic …

Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic
and lymphoid tissues was last updated in 2008. Since then, there have been numerous …

Abstract The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk
stratification of acute myeloid leukemia have been widely adopted, but have not yet been …

Refractoriness to induction chemotherapy and relapse after achievement of remission are
the main obstacles to cure in acute myeloid leukaemia (AML). After standard induction …

Menin inhibitors are novel targeted agents currently in clinical development for the treatment
of genetically defined subsets of acute leukemia. Menin has a tumor suppressor function in …

Background Despite the molecular heterogeneity of standard-risk acute myeloid leukemia
(AML), treatment decisions are based on a limited number of molecular genetic markers and …

Evidence of human acute myeloid leukemia stem cells (AML LSCs) was first reported nearly
2 decades ago through the identification of rare subpopulations of engrafting cells in …

The clinical and prognostic relevance of many recently identified driver gene mutations in
adult acute myeloid leukemia (AML) is poorly defined. We sequenced the coding regions or …

Therapy-related myeloid neoplasms (t-MN) arise as a late effect of chemotherapy and/or
radiation administered for a primary condition, typically a malignant disease, solid organ …

Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is
predominantly influenced by disease type and status, it is essential to be able to stratify …